HGSI reports Phase II NSCLC data

Human Genome Sciences (HGSI) said that in a Phase II trial of HGS-ETR1 to treat advanced non-small cell lung cancer (NSCLC), 29% (9/32) of patients achieved stable disease. The company would not say w...